Investor Presentaiton
Breyanzi (anti-CD 19 CART)
Indication
Phase/Study
# of Patients
R/R NHL
Phase I/II - TRANSCEND
N = 385
•
Breyanzi
Design
Study included R/R DLBCL, MCL, FL 3B, & PMBCL
Primary: ORR
Endpoints
Positive topline results in R/R MCL in April
2023
Status
.
Data presented as Late Breaker at ICML
2023 in R/R MCL
•
CT Identifier
NCT02631044
ll Bristol Myers Squibb Q3 2023 Results
Oncology
Hematology
Cell Therapy
Immunology
Cardiovascular
R/R iNHL
Phase II TRANSCEND FL
N = 213
3L+ CLL
Phase II - TRANSCEND CLL
N = 209
Breyanzi
iNHL includes 3L+ FL, 2L FL (high risk), 3L+ MZL
•
.
Primary: ORR
Positive topline results in R/R FL in April
2023
Data presented as Late Breaker at ICML
2023 in R/R FL
Projected data readout 2025 in 3L+ MZL
NCT04245839
Breyanzi
Breyanzi + ibrutinib
Breyanzi + venetoclax
• Primary: CRR
• Met primary endpoint in monotherapy arm
in January 2023
Data presented at ASCO 2023
NCT03331198
Not for Product Promotional Use
45View entire presentation